Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;20(10):597-614.
doi: 10.1038/s41585-023-00773-8. Epub 2023 May 24.

Urine biomarkers in bladder cancer - current status and future perspectives

Moritz Maas  1   2 , Tilman Todenhöfer  3   4 , Peter C Black  5
Affiliations
Review

Urine biomarkers in bladder cancer - current status and future perspectives

Moritz Maas et al. Nat Rev Urol. 2023 Oct.

Abstract

Urine markers to detect bladder cancer have been the subject of research for decades. The idea that urine - being in continuous contact with tumour tissue - should provide a vector of tumour information remains an attractive concept. Research on this topic has resulted in a complex landscape of many different urine markers with varying degrees of clinical validation. These markers range from cell-based assays to proteins, transcriptomic markers and genomic signatures, with a clear trend towards multiplex assays. Unfortunately, the number of different urine markers and the efforts in research and development of clinical grade assays are not reflected in the use of these markers in clinical practice, which is currently limited. Numerous prospective trials are in progress with the aim of increasing the quality of evidence about urinary biomarkers in bladder cancer to achieve guideline implementation. The current research landscape suggests a division of testing approaches. Some efforts are directed towards addressing the limitations of current assays to improve the performance of urine markers for a straightforward detection of bladder cancer. Additionally, comprehensive genetic analyses are emerging based on advances in next-generation sequencing and are expected to substantially affect the potential application of urine markers in bladder cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Compérat, E., Varinot, J., Moroch, J., Eymerit-Morin, C. & Brimo, F. A practical guide to bladder cancer pathology. Nat. Rev. Urol. 15, 143–154. (2018). - PubMed - DOI
    1. Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420–433. (2020). - PubMed - DOI
    1. Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J. Urol. 196, 1021–1029 (2016). - PubMed - DOI
    1. Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75–94 (2022). - PubMed - DOI
    1. Leal, J., Luengo-Fernandez, R., Sullivan, R. & Witjes, J. A. Economic burden of bladder cancer across the European Union. Eur. Urol. 69, 438–447 (2016). - PubMed - DOI

Publication types

Substances

LinkOut - more resources